Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer-Reference-Cited by-同舟云学术

Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer

Published:2019-10 Issue:29 Volume:15 Page:3381-3393
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Bobbili Priyanka¹,Ryan Kellie²,Duh Mei S¹,Dua Akanksha¹^ORCID,Fernandes Ancilla W²,Pavilack Melissa²,Gomez Jorge E³

Affiliation:

1. Analysis Group, Inc., Boston, MA 02199, USA

2. US Medical Affairs, AstraZeneca, Gaithersburg, MD 20878, USA

3. Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA

Abstract

Aim: To analyze treatment patterns and overall survival (OS) across time (2009–2014) among patients with unresected, stage III non-small-cell lung cancer (NSCLC). Patients & methods: Stage III NSCLC patients aged ≥65 years who initiated therapy were identified using SEER-Medicare data. Results: Among 4564 patients, 84% received chemotherapy (with or without radiotherapy), and 59% received chemoradiotherapy (CRT). Carboplatin + paclitaxel was the most frequent regimen. Median (interquartile range) OS among chemotherapy patients was 13.2 (6.0–28.9) months, and 14.8 (6.7–33.4) months among CRT patients. Among CRT patients, there was no difference in OS across years of CRT initiation. Conclusion: OS remained static across 2009–2014, indicating stagnancy in clinical outcomes for stage III NSCLC patients and a need for more effective therapeutic options.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2019-0282

Reference32 articles.

1. American Cancer Society. Cancer Facts and Figures 2018 (2018). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf

2. American Cancer Society. Non-small cell lung cancer survival rates, by stage (2017). www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html

3. American Cancer Society. Lung cancer (non-small cell) overview (2018). www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html

4. Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Single-Center Experience in Combined Oncological–Surgical Treatment for Resectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC);Diseases;2024-05-12

2. Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis;eClinicalMedicine;2023-10

3. Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis;Future Oncology;2023-05

4. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis;Lung Cancer;2022-12

5. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III Non-Small-Cell Lung Cancer: Results of KINDLE-Vietnam Cohort;Frontiers in Oncology;2022-05-23